1. Home
  2. HXHX vs XLO Comparison

HXHX vs XLO Comparison

Compare HXHX & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HXHX
  • XLO
  • Stock Information
  • Founded
  • HXHX 2003
  • XLO 2016
  • Country
  • HXHX China
  • XLO United States
  • Employees
  • HXHX N/A
  • XLO N/A
  • Industry
  • HXHX Trucking Freight/Courier Services
  • XLO Biotechnology: Pharmaceutical Preparations
  • Sector
  • HXHX Industrials
  • XLO Health Care
  • Exchange
  • HXHX Nasdaq
  • XLO Nasdaq
  • Market Cap
  • HXHX 36.9M
  • XLO 42.2M
  • IPO Year
  • HXHX 2025
  • XLO 2021
  • Fundamental
  • Price
  • HXHX $1.67
  • XLO $0.69
  • Analyst Decision
  • HXHX
  • XLO Buy
  • Analyst Count
  • HXHX 0
  • XLO 1
  • Target Price
  • HXHX N/A
  • XLO $4.00
  • AVG Volume (30 Days)
  • HXHX 159.6K
  • XLO 950.0K
  • Earning Date
  • HXHX 01-01-0001
  • XLO 08-07-2025
  • Dividend Yield
  • HXHX N/A
  • XLO N/A
  • EPS Growth
  • HXHX N/A
  • XLO N/A
  • EPS
  • HXHX 0.26
  • XLO N/A
  • Revenue
  • HXHX $25,571,810.00
  • XLO $9,274,000.00
  • Revenue This Year
  • HXHX N/A
  • XLO $300.08
  • Revenue Next Year
  • HXHX N/A
  • XLO $1.87
  • P/E Ratio
  • HXHX $6.33
  • XLO N/A
  • Revenue Growth
  • HXHX N/A
  • XLO N/A
  • 52 Week Low
  • HXHX $1.29
  • XLO $0.62
  • 52 Week High
  • HXHX $6.29
  • XLO $1.70
  • Technical
  • Relative Strength Index (RSI)
  • HXHX N/A
  • XLO 42.49
  • Support Level
  • HXHX N/A
  • XLO $0.65
  • Resistance Level
  • HXHX N/A
  • XLO $0.70
  • Average True Range (ATR)
  • HXHX 0.00
  • XLO 0.04
  • MACD
  • HXHX 0.00
  • XLO -0.01
  • Stochastic Oscillator
  • HXHX 0.00
  • XLO 19.51

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

Share on Social Networks: